Fetal methotrexate syndrome: A systematic review of case reports

Eline A. Verberne, Emma de Haan, J. Peter van Tintelen, Dick Lindhout, Mieke M. van Haelst

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establishment of the ‘fetal methotrexate syndrome’. However, it is unclear which congenital anomalies can truly be attributed to methotrexate exposure. The objective of this review is to delineate a consistent phenotype of the fetal methotrexate syndrome. We performed a systematic review that yielded 29 cases of (congenital) anomalies after in utero exposure to methotrexate and compared their malformation pattern to that of children and fetuses with congenital anomalies in general. Statistically significant higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in the methotrexate group, indicating that these congenital anomalies are truly part of the fetal methotrexate syndrome. These results aid clinicians with diagnosing fetal methotrexate syndrome.
Original languageEnglish
Pages (from-to)125-139
JournalReproductive Toxicology
Volume87
DOIs
Publication statusPublished - 1 Aug 2019
Externally publishedYes

Cite this

Verberne, Eline A. ; de Haan, Emma ; van Tintelen, J. Peter ; Lindhout, Dick ; van Haelst, Mieke M. / Fetal methotrexate syndrome: A systematic review of case reports. In: Reproductive Toxicology. 2019 ; Vol. 87. pp. 125-139.
@article{72928adc1ebb4404a4ac488d2af8b562,
title = "Fetal methotrexate syndrome: A systematic review of case reports",
abstract = "Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establishment of the ‘fetal methotrexate syndrome’. However, it is unclear which congenital anomalies can truly be attributed to methotrexate exposure. The objective of this review is to delineate a consistent phenotype of the fetal methotrexate syndrome. We performed a systematic review that yielded 29 cases of (congenital) anomalies after in utero exposure to methotrexate and compared their malformation pattern to that of children and fetuses with congenital anomalies in general. Statistically significant higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in the methotrexate group, indicating that these congenital anomalies are truly part of the fetal methotrexate syndrome. These results aid clinicians with diagnosing fetal methotrexate syndrome.",
author = "Verberne, {Eline A.} and {de Haan}, Emma and {van Tintelen}, {J. Peter} and Dick Lindhout and {van Haelst}, {Mieke M.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.reprotox.2019.05.066",
language = "English",
volume = "87",
pages = "125--139",
journal = "Reproductive Toxicology",
issn = "0890-6238",
publisher = "Elsevier Inc.",

}

Fetal methotrexate syndrome: A systematic review of case reports. / Verberne, Eline A.; de Haan, Emma; van Tintelen, J. Peter; Lindhout, Dick; van Haelst, Mieke M.

In: Reproductive Toxicology, Vol. 87, 01.08.2019, p. 125-139.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Fetal methotrexate syndrome: A systematic review of case reports

AU - Verberne, Eline A.

AU - de Haan, Emma

AU - van Tintelen, J. Peter

AU - Lindhout, Dick

AU - van Haelst, Mieke M.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establishment of the ‘fetal methotrexate syndrome’. However, it is unclear which congenital anomalies can truly be attributed to methotrexate exposure. The objective of this review is to delineate a consistent phenotype of the fetal methotrexate syndrome. We performed a systematic review that yielded 29 cases of (congenital) anomalies after in utero exposure to methotrexate and compared their malformation pattern to that of children and fetuses with congenital anomalies in general. Statistically significant higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in the methotrexate group, indicating that these congenital anomalies are truly part of the fetal methotrexate syndrome. These results aid clinicians with diagnosing fetal methotrexate syndrome.

AB - Methotrexate is a folic acid antagonist known to be teratogenic in humans. Several cases of congenital malformations after fetal exposure to methotrexate have been published, resulting in the establishment of the ‘fetal methotrexate syndrome’. However, it is unclear which congenital anomalies can truly be attributed to methotrexate exposure. The objective of this review is to delineate a consistent phenotype of the fetal methotrexate syndrome. We performed a systematic review that yielded 29 cases of (congenital) anomalies after in utero exposure to methotrexate and compared their malformation pattern to that of children and fetuses with congenital anomalies in general. Statistically significant higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in the methotrexate group, indicating that these congenital anomalies are truly part of the fetal methotrexate syndrome. These results aid clinicians with diagnosing fetal methotrexate syndrome.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067288100&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31181251

U2 - 10.1016/j.reprotox.2019.05.066

DO - 10.1016/j.reprotox.2019.05.066

M3 - Review article

VL - 87

SP - 125

EP - 139

JO - Reproductive Toxicology

JF - Reproductive Toxicology

SN - 0890-6238

ER -